Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Feb 8;20(1):2309693. doi: 10.1080/21645515.2024.2309693

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 The Author(s). Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.

PMC Copyright notice

Figure 3. — Anti-tumor impact of ESR1mut vaccines in a ERmut+ mouse mammary tumor model. (a) BALB/c mice were vaccinated with indicated virus and MM3MG-ESR1-Y537N cells were implanted two weeks post-vaccination and tumor growth measured biweekly. (b) spleens from mice in (a) were assessed by IFNγ ELISPOT assay (n = 5 mice/group). (c,d) BALB/c mice were implanted with MM3MG-ESR1-Y537N (c) or MM3MG-ESR1-Y537N-CD90.1 (d) expressing cells and vaccinated the following day with tumor growth measured bi-weekly (n = 5 mice/group). (e) Tumors from (d) were removed and CD90.1 expression was measured ex vivo as a surrogate of ESR1 expression. Shown as % of expression seen in control treated cells. Error bars represent SEM. *p < .05; **p < .05; ***p < .001. (f,g) Representative images and analysis (g) of MM3MG-ESR1-Y537N-CD90.1/ERE-Luc tumors vaccinated with ad-GFP control or ad-ESR1-Y537N as in (c,d).